SIMCERE PHARMA (02096) announced that the company proposes to spin off its subsidiary SIMCERE RENMING's H shares for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited (SEHK). The independent listing of SIMCERE RENMING's H shares on the SEHK Main Board constitutes a spin-off of SIMCERE RENMING by the company under Practice Note 15. The SEHK has confirmed that the company may proceed with the proposed spin-off.

On January 9, 2026, SIMCERE RENMING submitted the Application Form (Form A1) to the SEHK to apply for the listing of, and permission to deal in, its H shares on the Main Board. Under the plan, SIMCERE RENMING will conduct a new share offering for the proposed listing.

Subject to certain conditions, qualified shareholders will be provided with guaranteed quotas for SIMCERE RENMING H shares through preferential applications under the global offering. Upon completion of the proposed spin-off and the proposed listing, the company expects to retain an interest exceeding 50% in SIMCERE RENMING, which will consequently remain a subsidiary of the company.

SIMCERE RENMING is a biopharmaceutical enterprise at the forefront of global drug innovation, focusing on the research, development, and commercialization of innovative oncology drugs (excluding drugs related to cell therapies and genetic diagnosis and treatment technologies).